Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 2:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 138 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Cellular Repair Therapy Clear all
Completed Phase 3 Interventional Results available

GM-CSF Mouthwash for Preventing and Treating Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer

NCT00293462
View directory record Official record
Conditions
Head and Neck Cancer, Mucositis Oral, Radiation Toxicity, Tongue Cancer
Interventions
sargramostim, oral salt and soda mouthwash
Biological · Other
Lead sponsor
Marilyn Dodd
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 18, 2026, 2:48 AM EDT
Withdrawn Phase 2 Interventional

GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

NCT06046274
View directory record Official record
Conditions
Advanced Endometrial Cancer
Interventions
Pembrolizumab, Acasunlimab
Biological
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
2
States / cities
Orlando, Florida • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 29, 2024 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Study of Autologous Bone Marrow Derived Mononuclear Cells for Treatment of Ebstein Anomaly

NCT02914171
View directory record Official record
Conditions
Ebstein Anomaly
Interventions
Autologous Bone Marrow-derived Mononuclear Cells, Insertable cardiac monitor
Biological · Device
Lead sponsor
Timothy J. Nelson
Other
Eligibility
6 Months to 30 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Early Phase 1 Interventional

NIH CCR2 AAA Study

NCT04586452
View directory record Official record
Conditions
Abdominal Aortic Aneurysm (AAA), No Abdominal Aortic Aneurysm (Non-AAA)
Interventions
AAA Group (Aim 3A), Non-AAA Group, Ex Vivo Human AAA Specimens (Aim 2A), Relationship between radiotracer and CCR2 (Aim 2B), AAA Group (Aim 3B-Reproducibility)
Diagnostic Test · Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Sep 18, 2026, 2:48 AM EDT
Completed No phase listed Observational

Wound Complications in Head and Neck Surgery

NCT03134976
View directory record Official record
Conditions
Hypothyroidism; Surgery, Head and Neck Cancer, Wound Heal, Laryngeal Cancer, Laryngeal Fistula
Interventions
Levothyroxine
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 31, 2020 · Synced Sep 18, 2026, 2:48 AM EDT
Not listed Phase 1Phase 2 Interventional

Mesoblast Stem Cell Therapy for Patients With Single Ventricle and Borderline Left Ventricle

NCT03079401
View directory record Official record
Conditions
Hypoplastic Left Heart Syndrome, Atrioventricular Canal
Interventions
MPC; rexlemestrocel-L
Biological
Lead sponsor
Boston Children's Hospital
Other
Eligibility
Up to 5 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 20, 2023 · Synced Sep 18, 2026, 2:48 AM EDT
Not listed Phase 2 Interventional

Comparison of BioCart™II With Microfracture for Treatment of Cartilage Defects of the Femoral Condyle

NCT00729716
View directory record Official record
Conditions
Symptomatic Cartilage Defects of the Femoral Condyle
Interventions
BioCart™II, Microfracture
Biological · Procedure
Lead sponsor
ProChon Biotech Ltd
Industry
Eligibility
16 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
5
States / cities
Tucson, Arizona • Savannah, Georgia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2012 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Intra-coronary Infusion of Bone Marrow Derived Autologous CD34+ Selected Cells in Patients With Acute Myocardial Infarction

NCT00313339
View directory record Official record
Conditions
Myocardial Infarction, Coronary Artery Disease
Interventions
Intra-coronary infusion
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 17, 2013 · Synced Sep 18, 2026, 2:48 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Stromal Vascular Fraction From Lipoaspirate to Treatment of Chronic Non-healing Wound

NCT03882983
View directory record Official record
Conditions
Chronic Wounds
Interventions
Antria Cell Preparation Process
Drug
Lead sponsor
Antria
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
1
States / cities
Indiana, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 18, 2026, 2:48 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access for Single Patient Treatment of Autologous Human Schwann Cells (ahSC) for Peripheral Nerve Repair

NCT02480777
View directory record Official record
Conditions
Sciatic Nerve Injury
Interventions
Autologous Human Schwann cells
Biological
Lead sponsor
W. Dalton Dietrich
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Mar 4, 2019 · Synced Sep 18, 2026, 2:48 AM EDT
Recruiting Phase 3 Interventional

A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

NCT06952504
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel, Sacituzumab Tirumotecan, Cisplatin
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
1,123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
49
States / cities
Mobile, Alabama • Anchorage, Alaska • Irvine, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of MRG-001 in Wound Healing in Abdominoplasty Patients

NCT05844527
View directory record Official record
Conditions
Wound of Skin, Abdominal Wound
Interventions
MRG-001, Saline
Drug
Lead sponsor
MedRegen LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 7, 2025 · Synced Sep 18, 2026, 2:48 AM EDT
Recruiting Phase 2 Interventional

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

NCT05887609
View directory record Official record
Conditions
Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer
Interventions
Mirvetuximab Soravtansine-gynx, Olaparib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 100 Years · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
6
States / cities
Irvine, California • Aurora, Colorado • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 18, 2026, 2:48 AM EDT
Recruiting Phase 2 Interventional

Tislelizumab in People With Colorectal Cancer

NCT06529523
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Tislelizumab
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

NCT04095273
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Elimusertib (BAY1895344), Pembrolizumab (Keytruda®)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Sep 18, 2026, 2:48 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

NCT04104893
View directory record Official record
Conditions
Metastatic Castration Resistant Prostate Cancer
Interventions
Pembrolizumab
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
13
States / cities
San Francisco, California • West Los Angeles, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 2 Interventional Results available

Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene

NCT00588445
View directory record Official record
Conditions
Lung Cancer, Non-small Cell Lung Cancer, Bronchioloalveolar Cancer
Interventions
Gefitinib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Sep 18, 2026, 2:48 AM EDT
Recruiting Phase 3 Interventional

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

NCT06989112
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Trastuzumab deruxtecan, Rilvegostomig, Pembrolizumab, Carboplatin, Paclitaxel, Docetaxel
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Female only
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
61
States / cities
Tucson, Arizona • Little Rock, Arkansas • Duarte, California + 55 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 18, 2026, 2:48 AM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer

NCT02635672
View directory record Official record
Conditions
Neoplasms
Interventions
VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda, VIP152 (BAY 1251152) 15 mg
Drug
Lead sponsor
Vincerx Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
13
States / cities
Springdale, Arkansas • Louisville, Kentucky • Silver Spring, Maryland + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Sep 18, 2026, 2:48 AM EDT
Terminated Phase 1 Interventional Results available

Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism

NCT00282412
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Hematopoietic Stem Cell Transplantation, Fludarabine, Cyclophosphamide, Campath 1H, GCSF, Cyclosporins, Mycophenolate Mofetil
Biological · Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 60 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2016
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 29, 2018 · Synced Sep 18, 2026, 2:48 AM EDT
Not yet recruiting No phase listed Observational

Safety and Outcomes of MUSE Stem Cell Therapy in Individuals With Traumatic Brain Injury

NCT07326059
View directory record Official record
Conditions
Traumatic Brain Injury, Traumatic Brain Injury (TBI) Patients, Traumatic Brain Injury (TBI); Concussion, Initial Encounter, Traumatic Brain Injury (TBI); Concussion, Subsequent Encounter, Traumatic Brain Injury With Brief Loss of Consciousness, Traumatic Brain Injury With Persistent Cognitive Deficits
Interventions
MUSE Stem Cell Therapy
Biological
Lead sponsor
Healing Hope International
Other
Eligibility
6 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2036
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 18, 2026, 2:48 AM EDT
Recruiting Phase 2 Interventional

Efficacy of Locally Delivered Allogeneic Mesenchymal Stromal Cells

NCT05705024
View directory record Official record
Conditions
Corneal Ulcer
Interventions
Mesenchymal Stromal Cells, Control Solution
Biological · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 18, 2026, 2:48 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of REcycled CartiLage Auto/Allo IMplantation to Treat and Repair Focal Hip Cartilage Defects

NCT05553132
View directory record Official record
Conditions
Cartilage Defect
Interventions
Autologous Chondrocytes in their Pericellular Matrix (Chondrons) Coimplanted with Allogeneic Adipose-Derived Mesenchymal Stromal Cells (AMSCs) in a Fibrin Glue Carrier
Combination Product
Lead sponsor
Daniel B. F. Saris
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Sep 18, 2026, 2:48 AM EDT
Active, not recruiting Phase 2 Interventional

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)

NCT03767348
View directory record Official record
Conditions
Non-Small Cell Lung Cancer (NSCLC), Microsatellite Instability-High (MSI-H), Non-melanoma Skin Cancer (NMSC), Cutaneous Melanoma
Interventions
RP1, nivolumab
Biological
Lead sponsor
Replimune, Inc.
Industry
Eligibility
18 Years and older
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
26
States / cities
Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 18, 2026, 2:48 AM EDT